Diabetes Core Update: SGLT-2 inhibitors – Cardiovascular Effects– Sept. 2020

In this first episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the Cardiovascular Outcome Trials (CVOTs) of the SGLT-2 inhibitors, as well as the place of the SGLT-2is in the American Diabetes Association Guidelines and answer some common practical questions about SGLT-2 inhibitor use.  In episodes 2 and 3 of this series, Drs. Russell and Skolnik we will discuss the evidence about the effects of the SGLT-2 inhibitors on renal and heart failure outcomes.     

This special episode of the Diabetes Core Update was supported by an unrestricted educational grant from the Division of Cardiovascular & Metabolic Diseases of U.S. Medical at AstraZeneca Pharmaceuticals, LP. All material is intended for medical education purposes only and contains no promotional information.

For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health